HLX07 + HLX10 + mFOLFOX6

**HLX07 + HLX10 + mFOLFOX6** is an experimental combination regimen comprising three components: HLX07, HLX10, and mFOLFOX6. - **HLX07** is a recombinant, humanized monoclonal antibody that targets epidermal growth factor receptor (EGFR), functioning as an EGFR inhibitor—similar in mechanism to cetuximab. - **HLX10** is a recombinant, humanized anti-programmed cell death protein 1 (PD-1) monoclonal antibody, functioning as a PD-1 immune checkpoint inhibitor—similar in mechanism to pembrolizumab or nivolumab. - **mFOLFOX6** is a well-established chemotherapy regimen including oxaliplatin (platinum-based cytotoxic), fluorouracil (antimetabolite), and leucovorin (folinic acid, a biomodulator). This combination is under development primarily for cancer indications, leveraging direct cytotoxicity (from mFOLFOX6) along with dual targeted immunotherapies (HLX07, HLX10).